NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

AGREEMENT DEGREE BETWEEN SIMULTANEOUS REAL PHENOTYPE AND VIRTUAL PHENOTYPE IN PATIENTS FROM THE REALVIRFEN STUDY.

Perez-Elias MJ, Garcia-Arata I, Moreno S, Santos I, Sanz J, Moreno A, Lopez D, Gonzalez J, Dronda F, Antela A, Abraira V, Casado JL, Quereda C, Navas E; The Realvirfen study group; IAS Conference on HIV Pathogenesis and Treatment (2nd : 2003 : Paris, France).

Antivir Ther. 2003; 8 (Suppl.1): abstract no. 808.

Ramon y Cajal, Madrid, Spain

BACKGROUND: Interpretation of genotype resistance testing is one of the main unresolved issues in HIV resistance testing. Virtual Phenotype is a genotyping interpretation system with a good performance in the clinical practice. METHODS: We compared the agreement between Phenotype and Virtual Phenotype fold resistances present in samples from the Realvirfen study. We considered fold resistance as a binary categorical variable, resistant vs sensitive, using the new individualized biological cut-off. Agreement kappa coefficient was used to evaluate concordance. RESULTS: Seventy-seven Phenotype and Virtual Phenotype baseline paired samples. The median length of prior anti-retroviral therapy was 60 months (12-188), and 60% had been exposed to the three drug classes. Agreement %, Kappa coefficients: zidovudine 81, 0.6 +/-0.1; didanosine 93, 0.5 +/-0.2; zalcitabine 90, 0.2 +/-0.2; lamivudine 83, 0.7 +/-0.1; stavudine 88, 0.5 +/-0.2; abacavir 76, 0.3 +/-0.1; nevirapine 96, 0.9 +/-0.04; delavirdine 92, 0.8 +/-0.1; efavirenz 91, 0.8 +/-0.1; saquinavir 89, 0.8 +/-0.1; ritonavir 95, 0.9 +/-0.1; indinavir 91, 0.8 +/-0.1; nelfinavir 93, 0.9 +/-0.1; and amprenavir 83, 0.6 +/-0.1. An almost perfect kappa agreement or substantial has been observed for zidovudine, lamivudine, and non-nucleoside reverse transcriptase and protease inhibitors HIV fold resistance, whereas a fair or slight kappa coefficients were obtained for didanosine, zalcitabine, stavudine and abacavir. For drugs with poor concordance we observed discordances in both senses. CONCLUSIONS: Virtual Phenotype accurately predicts real phenotype resistance for the majority of the drugs. For poor agreement drugs the ability to predict virological response for real and virtual phenotype must be investigated.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acquired Immunodeficiency Syndrome
  • Anti-HIV Agents
  • Delavirdine
  • Didanosine
  • Dideoxynucleosides
  • Genotype
  • HIV
  • HIV Envelope Protein gp120
  • HIV Infections
  • HIV Protease Inhibitors
  • Humans
  • Lamivudine
  • Nevirapine
  • Phenotype
  • Ritonavir
  • Stavudine
  • Zalcitabine
  • Zidovudine
  • abacavir
  • genetics
  • immunology
  • reverse transcriptase, Human immunodeficiency virus 1
Other ID:
  • GWAIDS0023463
UI: 102263087

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov